氨磺必利和利培酮对精神分裂症伴抑郁和睡眠障碍疗效的对照研究  

A Comparative Study of Amisulpride and Risperidone in the Treatment of Schizophrenia with Depression and Sleep Disorders

作　　者：黄仁春 李晓丹 翁赛峥[1] 林明钦 HUANG Renchun;LI Xiaodan;WENG Saizheng;LIN Mingqin(Fuzhou Neuropsychiatric Hospital Affiliated to Fujian Medical University,Fuzhou 350008,China)

机构地区：[1]福建医科大学附属福州神经精神病医院,福州350008

出　　处：《世界睡眠医学杂志》2021年第4期598-599,共2页World Journal of Sleep Medicine

摘　　要：目的:探索分析氨磺必利和利培酮对精神分裂症伴发抑郁及睡眠障碍的效果。方法:选取2020年1月至3月福建医科大学附属福州神经精神病医院新入院2周未用药的精神分裂症伴发抑郁和睡眠障碍的患者86例作为研究对象,随机分为观察组和对照组,每组43例。观察组予以氨磺必利治疗,对照组使用利培酮治疗。8周后评测卡尔加精神分裂症抑郁量表(CDSS)、贝克抑郁自评量表(BDI)、阴性及阳性症状量表(PANSS)以及匹兹堡睡眠质量指数(PSQI)量表。结果:经过8周的治疗,观察组CDSS、BDI和PANSS量表中的抑郁和焦虑因子(PANSS-D)减分率明显高于对照组。观察组睡眠质量的改善明显好于对照组(P<0.05)。结论:氨磺必利对精神分裂症伴发的抑郁症状和睡眠障碍的疗效较利培酮更为优秀。Objective:To analysis the efficacy of amisulpride and risperidone on schizophrenia with depression and sleep disorders.Methods:The newly hospitalized schizophrenics with depression and sleep disorder were randomly divided into observation group and control group,with 43 cases each.The observation group was treated with amisulpride,while the control group was treated with risperidone.After 8 weeks,the patients were assessed with the Calgary Depression Scale for Schizophrenia(CDSS),Beck Depression Inventory(BDI),Positive and Negative Syndrome(PANSS)and Pittsburgh Sleep Quality Index(PSQI).Results:After 8 weeks of treatment,the reduction rate of CDSS,BDI and depression and anxiety factor(PANSS-D)in PANSS scale in the observation group was significantly higher than that in the control group.The improvement of sleep quality in the observation group was significantly better than that in the control group(P<0.05).Conclusion:Amisulpride is more effective than risperidone in the treatment of depressive symptoms and sleep disorders associated with schizophrenia.

关 键 词：精神分裂症伴发抑郁 氨磺必利 利培酮 睡眠障碍 

分 类 号：R338.63[医药卫生—人体生理学]